C2 CryoBalloon™ for Cryoablation
The innovative C2 CryoBalloon Ablation technology, designed for the precise treatment of Barrett's esophagus, squamous cancer and other diseased soft tissues.
C2 CryoBalloon technology operates through a regulated flow of liquid nitrous oxide, which transitions to gas at approximately -85°C, enabling rapid freezing and effective tissue necrosis.
This method ensures minimal structural damage and maintains the extracellular matrix of the treated tissue, resulting in reduction in post procedure pain compared to other ablative therapies.
Ready to Ablate a Wide Range
Highly safe and effective in treating both naive and refractory patients with Barrett’s esophagus. New catheter designs reach tubular structures, gastroesophageal junction (GEJ), and big and small lesions.
Enhanced Visualization in the Esophagus
The transparent compliant balloon pushes tissue flat, for better apposition and controlled therapeutic delivery. With advanced rotational and translational capabilities, physicians can selectively target and ablate diseased areas while sparing healthy tissue.
Intuitive controls give physicians total control of balloon inflation, deflation, diffuser positioning, and ablation.
Practice Integration made easy with Simplicity and Speed
Fast and easy-to-use
Streamlined procedure takes approximately
15 to 30 minutes, depending on the amount of BE present.
On-demand with simple storage
Compact, lightweight, and portable, C2 CryoBalloon features minimal set‑up time and disposable cartridges for easy storage.
Smart, intuitive interface
Hand‑held touchscreen controller provides system feedback to the user.
Patients Experience less post‑procedure Pain and Need for narcotic Medication
CryoBalloon ablation is significantly less painful than RFA..
Peak pain was lower after CryoBalloon ablation (median VAS 2 vs, 4, P < 0.01)
Duration of pain was shorter after CryoBalloon ablation (median 2 vs. 4 days, P < 0.01)
Mild pain was reported by 27% of patients immediately after cryoablation and by 14% after 2 days
No patient required narcotic medication after Day 7 following treatment.
Generating a Robust Clinical Data Pipeline in Barrett’s Esophagus and beyond
Highly effective and durable response through 2 years.
No disease progression noted in a single patient at 2 years (N=41)
No patient required narcotic medication after day 7 following treatment.
Median number of ablation procedures was 3.
